A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The treatment landscape for hepatitis C virus (HCV) infection has transformed over the past few decades, evolving from the limited efficacy of interferon (IFN) monotherapy to the highly successful pan-genotypic direct-acting antivirals (DAAs) used today. Initially, alpha-interferon monotherapy, introduced in the 1990s, was the standard treatment, yet it provided low sustained virological response (SVR) rates and caused significant adverse effects, limiting its utility. The development of pegylated interferon (peg-IFN) improved the pharmacokinetic profile of IFN, allowing for less frequent dosing and modestly improved response rates. When combined with ribavirin, peg-IFN achieved higher SVR rates, especially in non-genotype 1 HCV infections, but the combination also brought additional side effects, such as anemia and depression. The advent of the first-generation DAAs, such as telaprevir and boceprevir, marked a significant milestone. Combined with peg-IFN and ribavirin, these protease inhibitors boosted response rates in patients with genotype 1 HCV. However, high rates of adverse effects and drug resistance remained challenges. Second-generation DAAs, like sofosbuvir and ledipasvir, introduced IFN-free regimens with improved safety profiles and efficacy. The most recent advances are pan-genotypic DAAs, including glecaprevir-pibrentasvir and sofosbuvir-velpatasvir, which offer high SVR rates across all genotypes, shorter treatment durations, and fewer side effects. Current pan-genotypic regimens represent a cornerstone in HCV therapy, providing an accessible and effective solution globally.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
- Date Crossref
- 24/01/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Modena and Reggio Emilia Clinical and Experimental Medicine PhD Program pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Ospedaliero-Universitaria di Modena pays non établi dans la noticeÉtablissement de santé
-
Regione Siciliana pays non établi dans la noticeOrganisme public
-
University of Palermo Department of Health Promotion pays non établi dans la noticeUniversité ou école supérieure
-
Ospedale Buccheri la Ferla Fatebenefratelli pays non établi dans la noticeÉtablissement de santé
-
Azienda Ospedaliero-University Hospital of Mod Department of Oncology and Hematology pays non établi dans la noticeUniversité ou école supérieure
-
SIcilian Network for Therapy pays non établi dans la noticeInstitution
-
Buccheri-La Ferla Hospital Department of Medicine pays non établi dans la noticeÉtablissement de santé
Clinical and Experimental Medicine PhD Program — University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena et Regione Siciliana, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.